Dendritic cell vaccine - CreaGene

Drug Profile

Dendritic cell vaccine - CreaGene

Alternative Names: CreaVax-BC; CreaVax-HCC; CreaVax-HCC Inj.; CreaVax-PC; CreaVax-PC Inj.; CreaVax-RA Inj.; CreaVax-RCC; CreaVax-RCC Inj.; Dendritic cell vaccine for glioblastoma multiforme - CreaGene; Renal cell carcinoma vaccine - CreaGene/Dong-A

Latest Information Update: 17 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Creagene
  • Developer Dong-A ST; JW CreaGene
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase III Liver cancer
  • Phase II Rheumatoid arthritis
  • Phase I/II Glioblastoma; Prostate cancer

Most Recent Events

  • 02 Aug 2015 Phase I development for Prostate cancer is ongoing in South Korea
  • 09 Dec 2013 CreaGene initiates enrolment in the phase II IMMANUEL trial for Liver cancer in South Korea (KCT0000986)
  • 09 Aug 2013 Phase-II clinical trials in Rheumatoid arthritis (combination therapy) in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top